Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin plus R-CHP in first-line diffuse large B-cell lymphoma
ChiCTR2300077262Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jul 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanxi Cancer Hospital. Primary endpoint: Objective response rate. Started Jul 2023; status: recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300077262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077262.